FAAH

Cat. No.

A74606

CAS No.

2756099-59-7

Dual FAAH/sEH-IN-1

Dual FAAH/sEH-IN-1 is a potent dual inhibitor of soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 9.6 nM and 7 nM, respectively. This compound demonstrates significant antinociceptive effects during the inflammatory phase, making it a valuable tool for studying pain pathways and potential therapeutic interventions in pain management. Its ability to modulate lipid signaling pathways positions it for applications in neurobiology and pharmacology research.

Cat. No.

A74624

CAS No.

1186236-75-8

ST4070

ST4070 is a potent and selective reversible inhibitor of fatty acid amide hydrolase (FAAH). This compound elevates endocannabinoid levels in the brain, effectively counteracting neuropathic pain in preclinical animal models. Furthermore, ST4070 modulates endocannabinoid tone in brain regions associated with emotional regulation and produces significant anxiolytic-like effects in rodents. It is a valuable tool for research into neuropathic pain and anxiety disorders.

Cat. No.

A74625

CAS No.

546141-07-5

URB524

URB524 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH) through the aminoformylation of Ser241. This compound demonstrates significant analgesic, antidepressant, and anxiolytic properties, making it valuable for research in pain management, mood disorders, and anxiety studies. Its ability to modulate endocannabinoid levels positions URB524 as a crucial tool in the investigation of cannabinoid-related pathways and therapeutics.

Cat. No.

A74626

CAS No.

1357160-72-5

URB937

URB937 is a potent and peripherally restricted inhibitor of fatty acid amide hydrolase (FAAH), with an IC50 value of 26.8 nM. This compound effectively elevates anandamide levels, making it valuable for studies on endocannabinoid signaling. Due to its inability to cross the blood-brain barrier, URB937 is particularly useful for investigating peripheral FAAH activity and its implications in various biological processes and therapeutic applications.

Cat. No.

A74627

CAS No.

85075-82-7

Oleoyl ethyl amide

Synonyms: N-Ethyloleamide

Oleoyl ethyl amide is a selective fatty acid amide hydrolase (FAAH) inhibitor. This compound demonstrates potential in modulating bladder overactivity through its ability to enhance the endocannabinoid signaling pathway. Research applications include studies focused on urinary disorders and the broader investigation of endocannabinoid system effects on bladder function.

Cat. No.

A74628

CAS No.

1304778-15-1

TC-F2

TC-F2 is a reversible non-covalent inhibitor of fatty acid amide hydrolase (FAAH), exhibiting an IC50 of 28 nM. By modulating FAAH activity, TC-F2 is pertinent for research focused on various human diseases, including cancer, pain, inflammation, as well as neurological, metabolic, and cardiovascular disorders. This compound provides a valuable tool for investigating the therapeutic potential of FAAH inhibition in these areas.

Cat. No.

A74629

CAS No.

2128258-47-7

Sob-AM2

Sob-AM2 is a high-affinity substrate for fatty acid amide hydrolase (FAAH), exhibiting a Km of 1.3 μM and demonstrating effective blood-brain barrier permeability. This compound facilitates elevated delivery of Sobetirome to the central nervous system while minimizing peripheral exposure, thus activating central thyroid hormone receptor β (TRβ). Additionally, Sob-AM2 has been shown to protect against myelin and axon degeneration in models of experimental autoimmune encephalomyelitis (EAE), making it a valuable tool for investigating neuroprotective mechanisms and central nervous system disorders.

Cat. No.

A74632

CAS No.

1010096-65-7

FAAH/MAGL-IN-5

FAAH/MAGL-IN-5 is a potent inhibitor of both fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting equipotent inhibitory activity with an IC50 of 1.2 nM. This dual inhibition results in enhanced endocannabinoid levels, contributing to neuroprotective effects. FAAH/MAGL-IN-5 is valuable in research applications focused on pain management, neurodegenerative disorders, and the modulation of the endocannabinoid system.

Cat. No.

A74633

CAS No.

1515855-85-2

AKU-005

AKU-005 is a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting IC50 values of 63 nM and 389 nM for rat and human FAAH, respectively. This compound demonstrates significant potential in the study of trigeminal hyperalgesia and related pain pathways, making it a valuable tool for researchers investigating endocannabinoid signaling and pain modulation mechanisms.

Cat. No.

A74634

CAS No.

86855-26-7

AM 374

AM 374 is a potent inhibitor of fatty acid amide hydrolase (FAAH), demonstrating an IC50 value of 13 nM for amidase activity inhibition. This compound is utilized in research focused on neurological diseases, contributing to the understanding of endocannabinoid signaling pathways and their therapeutic potential in various conditions.

Cat. No.

A74636

CAS No.

256383-45-6

FAAH/MAGL-IN-4

FAAH/MAGL-IN-4 is a selective inhibitor of fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), exhibiting IC50 values of 9.1 nM and 7.9 μM, respectively. This compound plays a critical role in modulating endocannabinoid signaling pathways, making it valuable for investigating pain mechanisms and central nervous system disorders. Its potent inhibitory activity supports research in neurology and pain management applications.

Cat. No.

A74637

CAS No.

2244136-58-9

Irafamdastat

Synonyms: BMS-986368; CC-97489; ABX-1772

Irafamdastat is a potent inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting IC50 values of ≤ 100 nM for human FAAH and 100 nM-1 µM for human MAGL. This compound has demonstrated antiepileptic effects and is valuable for research into pain management, neuroprotection, and anxiety. Its dual inhibition of FAAH and MAGL positions it as a significant tool for exploring endocannabinoid system modulation in various therapeutic contexts.

Cat. No.

A74638

CAS No.

1143578-94-2

FAAH-IN-6

FAAH-IN-6 is a potent fatty acid amide hydrolase (FAAH) inhibitor that effectively crosses the blood-brain barrier, exhibiting IC50 values of 0.72 nM and 0.28 nM for human and rat FAAH, respectively. This compound demonstrates significant dose-dependent analgesic effects in preclinical models of neuropathic and inflammatory pain, making it valuable for research on pain management and therapeutic interventions targeting the endocannabinoid system.

Cat. No.

A74639

CAS No.

1942003-30-6

N-Nervonoyl taurine

Synonyms: (Z)-2-tetracos-15-enamidoethanesulfonic acid

N-Nervonoyl taurine, a fatty acid-taurine conjugate derived from nervonic acid, serves as a substrate for fatty acid amide hydrolase (FAAH). This compound plays a significant role in lipid metabolism and inflammation regulation. It is used in research applications focused on understanding FAAH's enzymatic activity and its implications in various physiological and pathological processes.

Cat. No.

A74640

CAS No.

847361-96-0

N-(3-Methoxybenzyl)Palmitamide

N-(3-Methoxybenzyl)Palmitamide is an inhibitor of fatty acid amide hydrolase (FAAH), which is crucial in the regulation of endocannabinoid signaling. This compound exhibits significant anti-inflammatory and analgesic properties, making it a valuable tool for research into pain relief and the treatment of central nervous system degenerative disorders. Its potential applications extend to studying the therapeutic effects of endocannabinoids in various biological contexts.

Cat. No.

A74641

CAS No.

1394894-41-7

JNJ-40355003

JNJ-40355003 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. It effectively enhances the levels of endocannabinoids, contributing to its biological activity in the modulation of pain, anxiety, and inflammation. This compound is valuable for research in cannabinoid signaling and therapeutic applications targeting the endocannabinoid system.

Cat. No.

A74642

CAS No.

887264-44-0

JP83

JP83 is an irreversible inhibitor of fatty acyl amide hydrolase (FAAH), demonstrating an IC50 of 1.6 nM in competitive activity-based protein profiling (ABPP) assays. This compound is valuable for studying the role of FAAH in regulating endocannabinoid signaling and its implications in pain modulation and various neurological disorders. Researchers utilize JP83 to elucidate the mechanistic pathways of FAAH inhibition and explore potential therapeutic applications in cannabinoid pharmacology.

Cat. No.

A74643

CAS No.

666860-59-9

SSR411298

SSR411298 is a selective and reversible inhibitor of fatty acid amide hydrolase (FAAH). This compound demonstrates significant potential in modulating endocannabinoid levels, making it a valuable tool for research related to post-traumatic stress disorder (PTSD) and other neuropsychiatric conditions. Its oral bioavailability further enhances its utility in various preclinical studies.

Cat. No.

A74644

CAS No.

887264-45-1

JP104

JP104 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH), exhibiting a potent pIC50 of approximately 8. This compound effectively modulates endocannabinoid levels, making it a valuable tool for studying pain management, neurobiology, and potential therapeutic applications in anxiety and stress-related disorders. Its mechanism of action provides unique insights into the biological pathways influenced by FAAH inhibition.

Cat. No.

A74646

CAS No.

906737-25-5

ASP 8477

ASP 8477 is a selective inhibitor of fatty acid amide hydrolase (FAAH), demonstrating IC50 values of 3.99 nM for human FAAH-1, 1.65 nM for the FAAH-1 (P129T) variant, and 57.3 nM for FAAH-2. This compound exhibits central nervous system activity, making it valuable in analgesia research. Its potent inhibition of FAAH positions ASP 8477 as a significant tool for studying pain modulation and endocannabinoid signaling pathways.

Cat. No.

A74647

CAS No.

898235-65-9

PF-622

PF-622 is a selective inhibitor of fatty acid amide hydrolase (FAAH), which plays a crucial role in the endocannabinoid system. This compound is utilized in research focused on analgesic, anxiolytic, and antidepressant effects, making it valuable for studies exploring pain management and mood disorders. Its ability to modulate endocannabinoid levels enables investigation into therapeutic strategies for various neurological conditions.

Cat. No.

A74648

CAS No.

2848719-34-4

FAAH/MAGL-IN-3

FAAH/MAGL-IN-3 is an irreversible inhibitor targeting fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) with IC50 values of 179 nM and 759 nM, respectively. This dual inhibitor is valuable for studying endocannabinoid metabolism and its implications in various physiological and pathological processes. Notably, FAAH/MAGL-IN-3 demonstrates low permeability in the PAMPA assay, indicating a potential for selective activity in research applications.

Cat. No.

A74649

CAS No.

875014-22-5

3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone

3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone is a potent inhibitor of fatty acid amide hydrolase (FAAH) with a pI50 of 5.89. This compound exhibits significant activity against endocannabinoids and lipid mediators, making it relevant for studies in pain management, inflammation, and cannabinoid signaling pathways. Its limited affinity for cannabinoid receptors CB(1) and CB(2) allows for targeted research into FAAH-related physiological processes without direct receptor modulation.

Cat. No.

A74650

CAS No.

1696401-38-3

FAAH/cPLA2α-IN-1

FAAH/cPLA2α-IN-1 is a dual inhibitor targeting fatty acid amide hydrolase (FAAH) and cytosolic phospholipase A2 alpha (cPLA2α), exhibiting IC50 values of 32 nM and 47 nM, respectively. This compound demonstrates potential anti-inflammatory properties by modulating lipid signaling pathways, making it valuable for research into pain management, neuroprotection, and inflammatory responses. Its use in various preclinical studies may provide insights into the therapeutic potential of FAAH and cPLA2α inhibition.

Cat. No.

A74651

CAS No.

1006604-91-6

MM-433593

MM-433593 is a selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1), targeting the endocannabinoid system to modulate pain and inflammation pathways. It demonstrates effective pharmacokinetic properties, including a biphasic elimination profile characterized by a rapid distribution and a slower elimination phase. With moderate oral bioavailability (14-21%), MM-433593 undergoes metabolism primarily through the oxidation of its indole ring's methyl group, yielding various sulfate, glucuronide, and glutathione-conjugated metabolites, making it a valuable tool for investigating FAAH-related biological processes and therapeutic applications.